Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.

ABSTRACT:

Background

Antiretroviral therapy (ART) management is challenging for individuals in resource-limited settings presenting for third-line treatment because of complex resistance patterns, partly due to reduced access to viral load monitoring. We aimed to evaluate use of newer antiretroviral drugs and contemporary management approaches, including population-based sequencing, to select appropriate antiretrovirals, plasma viral load monitoring, and interventions to improve adherence in individuals presenting with second-line viral failure.

Methods

A5288 was a phase 4, third-line ART strategy study done at 19 urban sites in ten countries that enrolled adult participants with confirmed plasma HIV-1 RNA (viral load) of 1000 copies per mL or more after more than 24 weeks of protease

SUBMITTER: Grinsztejn B 

PROVIDER: S-EPMC6857629 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature